20 results
P
patients with acute pancreatitis (AP)
I/C
fluid therapy protocols, types of fluids (Ringer lactate (RL), normal saline (NS), hydroxyethyl starch (HES)), routes and rates of administration
O
severe adverse events (SAE), organ failure, mortality, number of SAE, incidence of sepsis
P
adults
I/C
heterologous immunization schedules, homologous immunization schedules, different heterologous and homologous regimens
O
neutralizing antibodies against the original strain, serious adverse events (SAEs)
P
metastatic renal cell carcinoma (mRCC)
I/C
Immune checkpoint inhibitor (ICI) combination therapy, conventional tyrosine kinase inhibitor (TKI)-targeted therapy
O
severe adverse events (SAEs), fatal adverse events (FAEs), hematotoxicities, hepatotoxicities, gastrointestinal toxicities, endocrine toxicity, nephrotoxicity
P
COVID-19 patients
I/C
convalescent plasma therapy, control group
O
28-d mortality, length of hospital stay, ventilation-free days, 14-d mortality, improvements of symptoms, progression of diseases, requirements of mechanical ventilation, incidence of all adverse events (AEs), incidence of serious adverse events (SAEs)
P
Hypertrophic cardiomyopathy (HCM)
I/C
mavacamten, placebo
O
peak oxygen consumption (pVO2), New York Heart Association functional class (NYHA-FC), septal reduction therapy (SRT), serious adverse event (SAE), treatment emergency adverse event (TEAE), atrial fibrillation (AF), nonsustained ventricular tachycardia (NSVT
P
individuals
I/C
private SAE Level 3-5 AVs, ??
O
acceptance
P
heart failure patients
I/C
soluble guanylate cyclase (sGC) modulation, placebo
O
no significant difference in the risk of all-cause mortality, trend toward a considerable but non-significant increase in the incidence of SAEs, slight increase in hypotension and anemia, no effect on NT-proBNP levels, 6MWD, and mortality, improvement in EQ-5D-based quality of life
P
HCV-infected patients with stage 4-5 CKD
I/C
SOF-based DAA regimens
O
sustained viral response (SVR12)
P
COVID-19 patients
I/C
remdesivir, control group
O
Acute Kidney Injury (AKI)
P
1746
I/C
probiotics, synbiotics, fecal microbiota transplant (FMT), placebo/no treatment
O
reversed minimal HE (MHE), reduced overt HE (OHE) development, decreased ammonia levels, decreased NCT level, decreased hospitalization rates